SRI International has secured a seven-year, $150 million contract from the National Institutes of Health to provide development services for candidate HIV prevention products from investigator-initiated studies or from partnerships with other companies and organizations.
SRI said Tuesday its biosciences division will manufacture and characterize drug products to support the development of microbicide and non-vaccine pre-exposure agents through preclinical and clinical studies for the NIH’s National Institute of Allergy and Infectious Diseases and the Division of AIDS.
The company will also support activities that the Food and Drug Administration requires to move products into clinical tests.
Gita Shankar, an SRI director, has led a project to develop a multipurpose HIV prevention microbicide bioadhesive gel under an NIAID grant the company received in 2010.
SRI also produced drug products and supplied clinical sites with microbicides and contraceptive controls between 2000 and 2004.
